Therapeutics — Block, Degrade & Clear Spike
Catalog of COVID-19, Long COVID, and PASC interventions proposed to neutralize, enzymatically degrade, or physically remove spike protein — with explicit clinical support assessment (RCT, authorized, pilot, or preclinical only).
Interventions claimed to block spike–receptor binding, degrade spike protein, or clear circulating spike/autoantibodies. Clinical support tiers reflect published RCTs, authorization status, or preclinical data only.
| Claimed mechanism | Limitations | Source | ||||||
|---|---|---|---|---|---|---|---|---|
| Pemivibart (INV-202)Track on OSMF Research Tracker → | Monoclonal antibody | Receptor/entry blockade | block | FDA-authorized | No | Neutralizes spike; prevents ACE2 binding | Not approved for long COVID or vaccine-spike clearance | |
| SotrovimabTrack on OSMF Research Tracker → | Monoclonal antibody | Receptor/entry blockade | block | FDA-authorized | No | Spike neutralization (conserved epitope) | Acute COVID-19 only; limited variant coverage | |
| Evusheld (tixagevimab/cilgavimab)Track on OSMF Research Tracker → | Monoclonal antibody combo | Receptor/entry blockade | block | FDA-authorized | No | Dual spike neutralization | Prophylaxis only; not for established spike persistence | |
| Therapeutic apheresis / plasmapheresisTrack on OSMF Research Tracker → | Blood purification | Enzymatic or physical clearance | clear | Case series / pilot | Yes | Physical removal of circulating spike, autoantibodies, lipids | No large RCT; invasive; symptom improvement in subsets only | Achleitner M, et al. (2023)Opens in new tabClinicalTrials.gov (2024)Opens in new tab |
| SPEAR Trial (spike-directed apheresis)Track on OSMF Research Tracker → | Clinical trial | Enzymatic or physical clearance | clear | Ongoing trial | Yes | Protocolized spike reduction via apheresis | Results pending | ClinicalTrials.gov (2024)Opens in new tab |
| NattokinaseTrack on OSMF Research Tracker → | Protease supplement | Enzymatic or physical clearance | degrade | In vitro / in silico only | Yes | In vitro degradation of recombinant spike at 2.5–25 µg/mL | No human RCT for spike clearance; bleeding risk in pregnancy | Tanikawa T, et al. (2022)Opens in new tab |
| BromelainTrack on OSMF Research Tracker → | Protease supplement | Enzymatic or physical clearance | degrade | In vitro / in silico only | Yes | Spike degradation and competitive inhibition of spike–ACE2 binding | Limited spike-specific human data; bleeding caution in pregnancy | Sagar S, et al. (2021)Opens in new tab |
| Lumbrokinase / serrapeptaseTrack on OSMF Research Tracker → | Fibrinolytic enzymes | Enzymatic or physical clearance | indirect | Theoretical / review only | Yes | Fibrin degradation; proposed microclot clearance | No RCT for long COVID; indirect mechanism vs. direct spike degradation | Halma MTJ, Marik PE, Saleeby YM (2024)Opens in new tab |
| IvermectinTrack on OSMF Research Tracker → | Antiparasitic | Receptor/entry blockade | block | RCT negative/mixed | No | Docks to spike RBD-ACE2 interface (in silico/docking) | Docking study only; clinical RCTs failed primary endpoints | Various (2020)Opens in new tab |
| QuercetinTrack on OSMF Research Tracker → | Flavonoid | Receptor/entry blockade | block | RCT negative/mixed | Yes | TMPRSS2 inhibition; proposed ACE2/spike interface disruption (docking) | Bioavailability poor; long COVID RCT data lacking | Various (2022)Opens in new tab |
| Nicotine / α7nAChR agonismTrack on OSMF Research Tracker → | Cholinergic modulator | Anti-inflammatory / immunomodulatory | both | Theoretical / review only | Yes | α7nAChR agonism to counteract spike-mediated receptor downregulation; anti-inflammatory | Addiction liability; limited long COVID clinical trials | Tillman TS, Chen Q, Bondarenko V, Coleman JA, Xu Y, Tang P (2023)Opens in new tabVarious (2023)Opens in new tab |
| N-Acetylcysteine (NAC)Track on OSMF Research Tracker → | Antioxidant / mucolytic | Anti-inflammatory / immunomodulatory | both | Case series / pilot | Yes | Thiol/disulfide exchange weakens spike-ACE2 binding affinity; glutathione precursor | In vitro binding-affinity data; heterogeneous clinical endpoints | Various (2022)Opens in new tab |
| CurcuminTrack on OSMF Research Tracker → | Polyphenol | Anti-inflammatory / immunomodulatory | indirect | In vitro / in silico only | Yes | Virtual screening indicates spike/ACE2 binding inhibition | Poor bioavailability; no spike-clearance RCT | Various (2020)Opens in new tab |
| ColchicineTrack on OSMF Research Tracker → | Anti-inflammatory | Anti-inflammatory / immunomodulatory | indirect | RCT negative/mixed | No | Anti-inflammatory; indirect reduction of spike-mediated inflammation | Does not directly block or degrade spike | |
| MetforminTrack on OSMF Research Tracker → | Autophagy inducer (off-label proposals) | Autophagy induction | clear | Ongoing trial | Yes | Upregulates autophagy; proposed spike aggregate clearance | Autophagy hypothesis; no completed long COVID spike-clearance RCT | Halma MTJ, Marik PE, Saleeby YM (2024)Opens in new tab |
| Rapamycin (sirolimus)Track on OSMF Research Tracker → | mTOR inhibitor / autophagy inducer | Autophagy induction | clear | Theoretical / review only | Yes | Autophagy enhancement; proposed clearance of spike aggregates | No human long COVID RCT; immunosuppressive | Halma MTJ, Marik PE, Saleeby YM (2024)Opens in new tab |
| Spermidine / resveratrolTrack on OSMF Research Tracker → | Autophagy-promoting nutraceuticals | Autophagy induction | clear | In vitro / in silico only | Yes | Autophagy upregulation | No clinical spike-clearance validation | Halma MTJ, Marik PE, Saleeby YM (2024)Opens in new tab |
| Intermittent fasting / caloric restrictionTrack on OSMF Research Tracker → | Lifestyle intervention | Autophagy induction | clear | Theoretical / review only | Yes | Fasting-induced autophagy; proposed spike clearance | No controlled long COVID fasting RCT | Halma MTJ, Marik PE, Saleeby YM (2024)Opens in new tab |
| AzithromycinTrack on OSMF Research Tracker → | Antibiotic | Receptor/entry blockade | block | RCT negative/mixed | No | Proposed CD147 pathway interference (contested target) | Not spike-specific; CD147 as a spike coreceptor is itself scientifically contested | |
| Anti-CD147 antibody (meplazumab)Track on OSMF Research Tracker → | Monoclonal antibody | Receptor/entry blockade | block | Case series / pilot | No | Blocks CD147–spike interaction | CD147 as a direct spike-binding receptor is disputed by independent replication studies; limited Western regulatory approval | Wang K, et al. (2020)Opens in new tab |
| Nirmatrelvir/ritonavir (Paxlovid)Track on OSMF Research Tracker → | Antiviral | Antiviral (indirect) | indirect | FDA-approved (COVID-19) | Yes | Inhibits viral replication; may reduce spike production during active infection | Not designed for vaccine-derived spike clearance | |
| RemdesivirTrack on OSMF Research Tracker → | Antiviral | Antiviral (indirect) | indirect | FDA-approved (COVID-19) | No | Reduces viral replication → less neoantigen production | No role in established spike persistence without active infection | |
| NIH RECOVERTrack on OSMF Research Tracker → | Research program | Multi-modal research program | indirect | Ongoing trial | Yes | Multi-intervention long COVID trials | Not exclusively spike-targeted | NIH RECOVER Initiative (2024)Opens in new tab |
| NRICM101 (traditional formula)Track on OSMF Research Tracker → | Herbal compound | Multi-modal research program | indirect | Case series / pilot | Yes | Neurovascular protection in spike-administered hACE2 mice | Animal data; limited Western RCTs | Chang CC, et al. (2024)Opens in new tab |
| Hyperbaric oxygen (HBOT)Track on OSMF Research Tracker → | Adjunct therapy | Anti-inflammatory / immunomodulatory | indirect | Case series / pilot | Yes | Tissue oxygenation; proposed neurovascular recovery | Does not directly degrade spike; expensive | |
| Low-dose naltrexone (LDN)Track on OSMF Research Tracker → | Immunomodulator | Anti-inflammatory / immunomodulatory | indirect | Case series / pilot | Yes | Immune modulation in long COVID (not spike-specific) | No spike degradation/blockade demonstrated |
Clinical support legend
- FDA-approved/authorized — Regulatory approval for acute COVID-19 or prophylaxis; not necessarily long COVID or vaccine-spike clearance.
- RCT positive/negative — Randomized trial outcomes for claimed indication.
- Case series / pilot — Small human studies (e.g., Achleitner apheresis long-COVID cohort).
- In vitro only — No robust human efficacy (e.g., nattokinase 2.5–25 µg/mL cell-free degradation).
- Theoretical — Review or pharmacogenomic rationale without clinical validation.
Clinical caution
No intervention is established standard of care for vaccine-derived spike clearance. Nattokinase and bromelain carry bleeding-risk cautions in pregnancy/breastfeeding.
- Tanikawa T, et al. Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2. Molecules (2022). doi:10.3390/molecules27238405
- Sagar S, et al. Bromelain inhibits SARS-CoV-2 infection via targeting ACE-2, TMPRSS2, and spike protein. Clinical and Translational Medicine (2021). doi:10.1002/ctm2.281
- Halma MTJ, Marik PE, Saleeby YM Exploring autophagy in treating SARS-CoV-2 spike protein-related pathology. Endocrine and Metabolic Science (2024). doi:10.1016/j.endmts.2024.100163
- Achleitner M, et al. Clinical improvement of long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis. Molecular Psychiatry (2023). doi:10.1038/s41380-023-02084-1
- ClinicalTrials.gov SPEAR Trial — spike protein apheresis research. Clinical trial registry (2024)
- NIH RECOVER Initiative RECOVER — Researching COVID to Enhance Recovery. NIH program (2024)